Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 417-422 , April 2004

Nutrition and schizophrenia: beyond omega-3 fatty acids

  • Malcolm Peet

      Affiliations

    • Corresponding Author InformationTel.: +44-114-2872570; fax: +44-114-2879147

,Accepted 18 December 2003.

References 

  1. Jorm AF, Korten AE, Rodgers B, et al.  Helpfulness of interventions for mental disorders (beliefs of health professionals compared with the general public). Br. J. Psychiatry. 1997;171:233–237
  2. Geary A. The Food and Mood Handbook. London: Thorsons Publishers; 2001;
  3. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 1995;29:227–232
  4. Glen AL, Glen EM, Horrobin DF, et al.  A red cell membrane abnormality in a subgroup of schizophrenic patients (evidence for two diseases). Schizophr. Res. 1994;12:53–61
  5. Arvindakshan M, Sitasaward S, Debsikdar V, et al.  Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry. 2003;53:56–64
  6. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002;58:1–10
  7. Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II Fatty acid composition. Schizophr. Res. 1994;13:217–226
  8. Assies J, Lieverse R, Vreken P, Wanders RJA, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol. Psychiatry. 2001;49:510–522
  9. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in post mortem brains from schizophrenic patients. Schizopr. Res. 2000;42:7–17
  10. Hibbeln JR, Makino KK, Martin CE, Dickenson F, Boronow J, Fenton WS. Smoking, gender and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol. Psychiatry. 2003;53:431–441
  11. Hopper K, Wanderling J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia (results from ISOS, the WHO collaborative follow up project). Schizophr. Bull. 2000;26:835–846
  12. Jablensky N, Sartorius N, Ernberg G, et al.  A. Schizophrenia: manifestations, incidence and course in different cultures (a world health organisation ten-country study. Psychol. Med). Monograph Suppl. 1992;20:1–97
  13. World Health Organisation. Schizophrenia: An International Follow-up Study. Wiley, New York, 1979.
  14. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr. Scand. 1988;78:587–591
  15. Vaddadi KS, Gilleard CJ, Mindham RHS, Butler RA. A controlled trial of prostaglandin E precursor in chronic neuroleptic-resistant schizophrenic patients. Psychopharmacology. 1986;88:362–367
  16. Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. 1989;27:313–323
  17. Wolkin A, Jordan B, Peselow E, Rubenstein M, Petrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am. J. Psychiatry. 1986;143:912–914
  18. Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome (substrate pellagra). Biol. Psychiatry. 1981;16:837–850
  19. Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenia patients. Hum. Psychopharmacol. 1996;11:39–46
  20. Kay SR, Fiszbein A, Apler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  21. W. Guy, ECDEU Assessment Manual for Psychopharmacology. VS Department of Health, Education and Welfare, Washington, DC; US Government Printing Office, 1976, pp. 76–338.
  22. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry. 2000;61(Suppl. 4):10–14
  23. Peet M, Brind J, Ramchand CN, Shah S, Vanka GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001;49:243–251
  24. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatry Res. 2003;36:7–18
  25. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable MA. Placebo-controlled trial of omega-3 fatty acid (ethyl eiscosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry. 2001;158:2017–2074
  26. Emsley RA, Mybury CC, Oosthuizen PP, Van Rensburgh SJ. Randomised placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry. 2002;159:1596–1598
  27. M. Peet, Dietary predictors of schizophrenia and depression. Presented at Nineth European Nutritional Conference, Rome, 2003.
  28. Gorski JA, Zeiler SR, Tamonski S, Jones KR. Brain-derived neurotrophic fator is required for the maintenance of cortical dendrites. J. Neurosci. 2003;23:6856–6865
  29. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla FA. High-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience. 2002;112:803–814
  30. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry. 2003;8:5610–5920
  31. Trowell HC, Burkitt DP. Western Diseases (their Emergence and Prevention). London: Edward Arnold; 1983;
  32. Torrey EF. Schizophrenia and Civilisation. New York: Jason Aronson; 1980;
  33. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders (a systematic review of the literature). Can. J. Psychiatry. 2002;47:833–843
  34. Torrey EF, Miller J. The Invisible Plague. New Bunswick: Rutgers University Press; 2001;
  35. Scull A. Was insanity increasing. A response to Edward Hare. Br. J. Psychiatry. 1984;144:432–436
  36. Cooper JE, Sartorius N. Cultural and temporal variations in schizophrenia (a speculation on the importance of industrialisation). Br. J. Psychiatry. 1977;130:50–55
  37. Hare E. Schizophrenia as a recent disease. Br. J. Psychiatry. 1988;153:521–531
  38. Knapp VJ. Major dietary changes in nineteenth century Europe. Perspect. Biol. Med. 1988;31:188–193
  39. Cleave TL. The Saccharine Disease. Bristol: John Wright & Sons; 1974;
  40. Eaton SB, Konner M, Schostak M. Stone agers in the fast lane (chronic degenerative diseases in evolutionary perspective). Am. J. Med. 1988;84:739–749
  41. Eaton SB, Eaton SB, Konner MJ. Paleolithic nutrition revisited (a twelve year retrospective on its nature and implications). Eur. J. Clin. Nutr. 1997;51:207–216
  42. Leaf A, Weber PC. A new era for science in nutrition. Am. J. Clin. Nutr. 1987;45:1048–1053
  43. L. Henderson, J. Gregory, G. Simon, The National Diet and Nutrition Survey: Adults Aged 19 to 65. HMSO, London, 2002.
  44. McCreadie R, Macdonald E, Blacklock C, et al.  Dietary intake of schizophrenic patients in Nithsdale, Scotland (case-control study). Br. Med. J. 1998;317:784–785
  45. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999;29:697–701
  46. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment; the metabolic syndrome. Life Sci. 2002;71:239–257
  47. Hanson BC. The metabolic syndrome X. Ann. NY Acad. Sci. 1999;892:1–24
  48. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first episode, drug-naı̈ve patents with schizophrenia. Am. J. Psychiatry. 2003;160:284–289
  49. Duan W, Guo Z, Jiang H, Ware M, Mattson MP. Reversal of behavioural and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology. 2003;144:2446–2453
  50. Pauling L. Orthomolecular psychiatry, varying the concentrations of substances normally present in the human body may control mental disease. Science. 1968;160:265–271

PII: S0952-3278(04)00016-X

doi: 10.1016/j.plefa.2003.12.019

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 417-422 , April 2004

Article Tools

* Image Usage & Resolution